Vijay Singh, MD
Rheumatology · Sewell, NJNPI 1174786297
Payments from drug & device makers
Across 499 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$1K
- UCB, Inc.$779
- Johnson & Johnson$620
- ANI Pharmaceuticals, Inc.$580
- AstraZeneca$503
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,35998%
- Education$1862%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 104 | $1,408 |
| Amgen(2 entities) | 74 | $1,045 |
| UCB, Inc. | 55 | $779 |
| Johnson & Johnson | 33 | $620 |
| ANI Pharmaceuticals, Inc. | 24 | $580 |
| AstraZeneca(2 entities) | 32 | $503 |
| Novartis | 27 | $462 |
| E.r. Squibb & Sons, L.L.C. | 33 | $399 |
| Pfizer | 28 | $383 |
| GSK | 20 | $286 |
| Lilly USA, LLC | 6 | $88 |
| Fresenius Kabi USA, LLC | 5 | $80 |
| Sanofi | 4 | $79 |
| Organon | 6 | $79 |
| Aurinia Pharma U.S., Inc. | 5 | $77 |
| Fidia Pharma USA Inc. | 4 | $69 |
| Genentech USA, Inc. | 4 | $63 |
| Boehringer Ingelheim | 3 | $59 |
| Sandoz | 3 | $56 |
| Radius Health, Inc. | 3 | $51 |
| Mallinckrodt Enterprises LLC | 3 | $40 |
| Orthogenrx Inc. | 3 | $39 |
| Sobi, Inc | 3 | $38 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $33 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $29 |
| Pacira Therapeutics, Inc. | 2 | $28 |
| Si-bone, Inc. | 1 | $19 |
| Invivyd Inc | 1 | $18 |
| Almatica Pharma LLC | 1 | $18 |
| Cumberland Pharmaceuticals, Inc. | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Pacira Pharmaceuticals Incorporated | 1 | $13 |
| Sebela Pharmaceuticals Inc. | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,545 in reported general payments places this provider in the 70th percentile of 234 rheumatology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 114 | $920,378 |
| RemicadeInfliximab | 104 | $779,196 |
| Cimzia (2 Pack)Certolizumab Pegol | 88 | $611,942 |
| BenlystaBelimumab | 154 | $508,189 |
| Enbrel SureclickEtanercept | 59 | $466,501 |
| ProliaDenosumab | 240 | $428,090 |
| OrenciaAbatacept/Maltose | 81 | $407,571 |
| Simponi AriaGolimumab | 48 | $332,077 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 17 | $202,904 |
| ActemraTocilizumab | 40 | $183,686 |
| Teriparatide | 57 | $166,647 |
| Xeljanz XrTofacitinib Citrate | 25 | $142,893 |
| SaphneloAnifrolumab-Fnia | 28 | $142,869 |
| KevzaraSarilumab | 23 | $96,086 |
| Taltz AutoinjectorIxekizumab | 14 | $95,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonRemicade, Simponi Aria, Simponi | $620 | $1,180,428164 claims |
| UCB, Inc.Cimzia (2 Pack) | $779 | $611,94288 claims |
| GSKBenlysta | $286 | $508,189154 claims |
| AmgenProlia, Otezla | $1,045 | $500,123255 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $399 | $407,57181 claims |
| AstraZenecaSaphnelo | $503 | $142,86928 claims |
| SanofiKevzara | $79 | $96,08623 claims |
| Lilly USA, LLCForteo | $88 | $56,64813 claims |
| Scilex Pharmaceuticals Inc.Ztlido, Colchicine | $16 | $17,16667 claims |
| AbbVieSavella | $1,408 | $14,06612 claims |
| PfizerLyrica | $383 | $12,17816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 234 rheumatology providers in New Jersey.
Other rheumatology in Sewell
- Nickolas TyrisSewell$201K
- Neil KramerSummit$1.8M
- Lori CoxNew Brunswick$1.4M
- Joshua SundharVoorhees$1.3M
- Richard HaddadRed Bank$1.1M
- Kiren SahniWest Long Branch$730K
- Ramesh KumarToms River$504K
- Hisham El KadiFreehold$480K
- Jeffrey GreenbergSummit$451K
- Adrienne HollanderVoorhees$441K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.